Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders.
cluster headache
demand-valve oxygen
masks
migraine disorders
oxygen inhalation therapy
trigeminal autonomic cephalalgias
Journal
Journal of clinical neurology (Seoul, Korea)
ISSN: 1738-6586
Titre abrégé: J Clin Neurol
Pays: Korea (South)
ID NLM: 101252374
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
17
09
2021
revised:
05
01
2022
accepted:
05
01
2022
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
20
5
2022
Statut:
ppublish
Résumé
Oxygen therapy (OT) can relieve head pain in certain primary headache disorders, including cluster headache (CH). The exact underlying mechanism is currently uncertain, but suggested mechanisms include inhibition of the trigeminoautonomic reflex, modulation of neurotransmitters, and cerebral vasoconstriction. OT is the standard for acute treatment of CH, but patients with CH often experience considerable difficulties accessing home OT due to problems with insurance coverage. Inhalation of 100% oxygen at 6-12 L/min for 15-30 min using a non-rebreather face mask is one of the most effective acute therapies for CH, but several trials have indicated the superiority of higher oxygen flow rates of up to 15 L/min and/or using a demand-valve oxygen mask that can produce very high flow rates. Two randomized controlled trials have demonstrated the efficacy of OT in migraine, but obtaining reliable evidence is considered difficult because of different inhalation protocols, varying outcome measures, and small samples. There are some reports on the efficacy of OT as an adjuvant therapy in hypnic headache, primary headache in the emergency department, and even postdural puncture headache. The goal of this review article is to expand the knowledge regarding the use of oxygen in the treatment of headache disorders.
Identifiants
pubmed: 35589316
pii: 18.271
doi: 10.3988/jcn.2022.18.3.271
pmc: PMC9163947
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
271-279Informations de copyright
Copyright © 2022 Korean Neurological Association.
Déclaration de conflit d'intérêts
Dr. Mo was involved as a site investigator of multicenter trial sponsored Biohaven Asia Pacific Ltd. Dr. Cho was involved as a site investigator of multicenter trial sponsored Otsuka Korea, Allergan, Ildong Pharmaceutical Co., LTD, Novartis International AG, Eli Lilly and Company, Hyundaipharm. Co. Ltd., Biohaven Asia Pacific Ltd, H. Lundbeck A/S (Lundbeck), and Parexel Korea Co., Ltd., and received lecture honoraria from Allergan Korea, WhanIn Pharm Co., LTD, Shinpoong Pharma. Co., Ltd, and SK chemicals in the past 24 months. Dr. Chung reported no conflict of interest. Dr. Rozen nothing to disclose, no conflict of interest.
Références
Eur J Neurol. 2006 Oct;13(10):1066-77
pubmed: 16987158
Curr Opin Neurol. 2019 Jun;32(3):432-437
pubmed: 30893102
Med Gas Res. 2019 Oct-Dec;9(4):229-231
pubmed: 31898608
Headache. 2007 Jul-Aug;47(7):1079-84
pubmed: 17635600
J Neurosurg. 2010 May;112(5):1080-94
pubmed: 19852540
J Neurosci. 2007 Apr 11;27(15):4036-44
pubmed: 17428981
Am J Respir Cell Mol Biol. 1998 Oct;19(4):573-81
pubmed: 9761753
Headache. 2016 Jul;56(7):1093-106
pubmed: 27432623
Headache. 2018 May;58(5):688-699
pubmed: 29536529
Cephalalgia. 2021 Apr;41(5):525-534
pubmed: 33203216
Headache. 1963 Jan;2:214-27
pubmed: 13964041
Ann Intern Med. 1980 Sep;93(3):391-8
pubmed: 6776858
Cephalalgia. 2017 Mar;37(3):214-224
pubmed: 27013239
J Clin Neurol. 2021 Apr;17(2):229-235
pubmed: 33835743
Front Neurol. 2018 Oct 26;9:908
pubmed: 30416482
Headache. 2009 Sep;49(8):1131-43
pubmed: 19719541
Cephalalgia. 2021 Aug;41(9):968-978
pubmed: 33631965
J Lancet. 1952 Feb;72(2):92-8
pubmed: 14908316
Respir Med. 2008 Jul;102(7):1021-5
pubmed: 18359215
Mayo Clin Proc. 1987 Sep;62(9):841-7
pubmed: 3114573
Cephalalgia. 2017 Apr;37(4):396-398
pubmed: 27121359
Ther Clin Risk Manag. 2015 Nov 09;11:1687-96
pubmed: 26635477
J Neurol. 2013 Oct;260(10):2596-605
pubmed: 23852659
Cephalalgia. 2016 Sep;36(10):970-9
pubmed: 26566938
Cephalalgia. 2007 Jul;27(7):824-32
pubmed: 17598764
Curr Pain Headache Rep. 2012 Jan 29;:
pubmed: 22286556
J Headache Pain. 2018 Sep 3;19(1):78
pubmed: 30178397
Headache. 2018 Nov;58(10):1568-1578
pubmed: 30221765
Arch Neurol. 1985 Apr;42(4):362-3
pubmed: 3885921
Headache. 2017 Oct;57(9):1428-1430
pubmed: 28857152
Cochrane Database Syst Rev. 2015 Dec 28;(12):CD005219
pubmed: 26709672
Am J Emerg Med. 2020 Dec;38(12):2625-2628
pubmed: 33041133
J Headache Pain. 2018 Oct 10;19(1):94
pubmed: 30306284
Headache. 1981 Jan;21(1):1-4
pubmed: 7007285
Rev Med Interne. 2019 Oct;40(10):670-676
pubmed: 31054779
Headache. 2017 Oct;57(9):1416-1427
pubmed: 28842974
Cephalalgia. 2010 Dec;30(12):1435-42
pubmed: 20974580
Headache. 2019 Feb;59(2):235-249
pubmed: 30632614
Cephalalgia. 2013 Jan;33(1):65-7
pubmed: 23136209
J Clin Neurol. 2019 Jan;15(1):90-96
pubmed: 30618222
Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1137-1156
pubmed: 30074553
J Neurol Sci. 2012 Jun 15;317(1-2):17-28
pubmed: 22482825
Cephalalgia. 2017 Jul;37(8):730-736
pubmed: 27206964
Pain Med. 2013 Apr;14(4):455-9
pubmed: 23369112
Headache. 1996 Jul-Aug;36(7):429-32
pubmed: 8783475
JAMA. 2009 Dec 9;302(22):2451-7
pubmed: 19996400
Nat Neurosci. 2007 Jun;10(6):754-62
pubmed: 17468748
Orphanet J Rare Dis. 2008 Jul 23;3:20
pubmed: 18651939